Monday, 3 December 2012

Eradication regimens have poor efficacy against H. pylori in China

Most of the first and second line eradication drug regimens have poor efficacy against H. pylori infection in Chinese patients, a study from Nanjing has shown.
Researchers from the Department of Gastroenterology at the First Affiliated Hospital of Nanjing Medical University assessed the efficacy of standard sequential therapy for H pylori (five days of treatment with a proton pump inhibitor [PPI] and an antibiotic such as amoxicillin followed by five days of treatment with the PPI and two other antibiotics such as clarithromycin and tinidazole) and the efficacy of levofloxacin-containing triple therapy and levofloxacin-containing sequential therapy.
Their study showed that the H pylori eradication rate was 83% for the standard sequential therapy compared to 81% for levofloxacin-containing triple therapy and 87% for levofloxacin-containing sequential therapy.
The researchers conclude that : "standard sequential therapy and seven-day levofloxacin triple therapy produce unacceptably [low] therapeutic efficacy in China. Only levofloxacin-containing sequential therapy achieved borderline acceptable result. None of the regimens tested reliably achieved 90% or greater therapeutic efficacy in China."
Read more: Helicobacter

No comments:

Post a comment

Add a comment